Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 16;14(4):513.
doi: 10.3390/life14040513.

Insights into the Novel Cardiac Biomarker in Acute Heart Failure: Mybp-C

Adriana Chetran  1   2 , Minerva Codruţa Bădescu  1   3 , Ionela Lăcrămioara Şerban  4 , Ştefania Teodora Duca  1   2 , Irina Afrăsânie  1   2 , Maria-Ruxandra Cepoi  1   2 , Bianca Ana Dmour  1   3 , Iulian Theodor Matei  1   2 , Mihai Ştefan Cristian Haba  1   2 , Alexandru Dan Costache  1   5 , Ovidiu Mitu  1   2 , Corina Maria Cianga  6   7 , Cristina Tuchiluş  8   9 , Daniela Constantinescu  6   7 , Irina Iuliana Costache-Enache  1   2
Affiliations

Insights into the Novel Cardiac Biomarker in Acute Heart Failure: Mybp-C

Adriana Chetran et al. Life (Basel). .

Abstract

(1) Background: Given its high cardiac specificity and its capacity to directly assess the cardiac function, cardiac myosin-binding protein (MyBP-C) is a promising biomarker in patients with acute heart failure (AHF). The aim of our study was to investigate the clinical utility of this novel marker for diagnosis and short-term prognosis in subjects with AHF. (2) Methods: We measured plasma levels of MyBP-C at admission in 49 subjects (27 patients admitted with AHF and 22 controls). (3) Results: The plasma concentration of MyBP-C was significantly higher in patients with AHF compared to controls (54.88 vs. 0.01 ng/L, p < 0.001). For 30-day prognosis, MyBP-C showed significantly greater AUC (0.972, p < 0.001) than NT-proBNP (0.849, p = 0.001) and hs-TnI (0.714, p = 0.047). In a multivariate logistic regression analysis, an elevated level of MyBP-C was the best independent predictor of 30-day mortality (OR = 1.08, p = 0.039) or combined death/recurrent 30-days rehospitalization (OR = 1.12, p = 0.014). (4) Conclusions: Our data show that circulating MyBP-C is a sensitive and cardiac-specific biomarker with potential utility for the accurate diagnosis and prognosis of AHF.

Keywords: MyBP-C; acute heart failure; biomarker; cardiac myosin-binding protein; diagnosis; prognosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Combined receiver operating characteristic (ROC) curves for NT-proBNP, MyBP-C and hs-TnI for the diagnosis of AHF in dyspneic patients.
Figure 2
Figure 2
Median MyBP-C levels among HF patients who died (n = 9) within 30 days and those who survived (n = 18). Boxes = interquartile ranges; whiskers = 5th and 95th percentiles.
Figure 3
Figure 3
ROC curve for the relationship between cardiac biomarkers and total mortality rate within 30 days.
Figure 4
Figure 4
ROC curve for the relationship between cardiac biomarkers and rehospitalization rate within 30 days.
Figure 5
Figure 5
Kaplan–Meier survival curves according to the high-risk cut-off.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Ziaeian B., Fonarow G.C. Epidemiology and Aetiology of Heart Failure. Nat. Rev. Cardiol. 2016;13:368–378. doi: 10.1038/nrcardio.2016.25. - DOI - PMC - PubMed
    1. Groenewegen A., Rutten F.H., Mosterd A., Hoes A.W. Epidemiology of Heart Failure. Eur. J. Heart Fail. 2020;22:1342–1356. doi: 10.1002/ejhf.1858. - DOI - PMC - PubMed
    1. Task Force Members. McDonagh T.A., Metra M., Adamo M., Gardner R.S., Baumbach A., Böhm M., Burri H., Butler J., Čelutkienė J., et al. 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure: Developed by the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC). With the Special Contribution of the Heart Failure Association (HFA) of the ESC. Eur. J. Heart Fail. 2022;24:4–131. doi: 10.1002/ejhf.2333. - DOI - PubMed
    1. Writing Committee Members; ACC/AHA Joint Committee Members 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. J. Card. Fail. 2022;28:e1–e167. doi: 10.1016/j.cardfail.2022.02.010. - DOI - PubMed
    1. Farmakis D., Parissis J., Lekakis J., Filippatos G. Acute Heart Failure: Epidemiology, Risk Factors, and Prevention. Rev. Esp. Cardiol. Engl. Ed. 2015;68:245–248. doi: 10.1016/j.recesp.2014.11.009. - DOI - PubMed